Some of the generic drops have become expensive because of consolidation. For example, generic pred forte drops used to be very inexpensive but now there are only two companies that make it and those two companies are owned by the same two large pharmaceuticals that own the branded medicines, hence the price of the generic is almost the same as the expensive branded options. The price of drugs does vary from one pharmacy to another and each insurance plan has its preferred drugs which cost much less for patients depending on the deals they have made with the manufactures. For example brand A might be priced well at one store because they have made a good deal with the manufacturer and made it their preferred drug while brand B would be expensive. Across town a different drug store chain might have a great price for B and a high price for A because they have make B their preferred drug and have a great volume price with the manufacturer.
Alas, it is hard to find a cost effective way to protect your eyes around cataract surgery.
FDA approves Genentech's Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States. Press release issued by Genentech in April 2017.
Alimera Sciences provides details on FDA approval of Iluvien as the first long-term treatment for diabetic macular edema. Press release issued by Alimera Sciences in September 2014.
Allergan announces FDA approves revised indication for Ozurdex (dexamethasone intravitreal implant) mg for the treatment of diabetic macular edema. Press release issued by Allergan in September 2014.
Allergan receives FDA approval for Ozurdex (dexamethasone intravitreal implant) mg as treatment option for use in certain patients with diabetic macular edema. Press release issued by Allergan in June 2014.
Treatment of diffuse diabetic macular oedema using steroid eye drops. Acta Ophthalmologica. November 2012.
FDA approves Lucentis to treat diabetic macular edema. FDA press release issued in August 2012.
Dexamethasone drug delivery system (Ozurdex) for the treatment of refractory diabetic macular oedema: retrospective case series analysis. Acta Ophthalmologica. Published online ahead of print in August 2012.
Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology . April 2012.
Long-term safety, high-resolution imaging, and tissue temperature modeling of subvisible diode micropulse photocoagulation for retinovascular macular edema. Retina. Published online ahead of print, November 2011.
The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology . April 2011.
National Diabetes Fact Sheet: National estimates and general information on diabetes and prediabetes in the United States, 2011. Department of Health and Human Services, Centers for Disease Control and Prevention. 2011.
Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine . July 2010.
Diabetic retinopathy. Cleveland Clinic: Current Clinical Medicine, 2nd ed. 2010.
Serous detachment of the neural retina. Ophthalmology, 3rd ed. 2008.
Comparison of the Modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Archives of Ophthalmology. April 2007.